Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
Bianca Weinstock‐Guttman(Jacobs Institute), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Mark S. Freedman(University of Ottawa), Deidre Kile, Gary Cutter(Epilepsy Foundation), Anthony T. Reder(University of Chicago), Bruno Musch, Robert A Bermel(Cleveland Clinic), Xiaoye Ma, Thomas Leist(Thomas Jefferson University)
Cited by 23
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k